Shingrix™ (zoster vaccine recombinant, adjuvanted) – New drug approval

- On October 20, 2017, GlaxoSmithKline announced the FDA approval of Shingrix (zoster vaccine recombinant, adjuvanted), for the prevention of herpes zoster (shingles) in adults aged 50 years and older.

  — Shingrix is not indicated for prevention of primary varicella infection (chickenpox).

- Shingles is a condition caused by the varicella zoster virus (VZV), the same virus that causes chickenpox. Nearly all older adults have VZV dormant in their nervous system, which can reactivate with advancing age.

  — There are an estimated 1 million cases of shingles in the U.S. each year, and one in three Americans will develop the condition in their lifetime.
  — Shingles presents as a painful, itchy rash that develops on one side of the body and can last for 2 to 4 weeks. The pain associated with shingles is often described as burning, shooting, or stabbing, and even once the rash is gone, a person can experience postherpetic neuralgia (PHN) pain, lasting from at least 3 months to several years.

- Shingrix is a non-live, recombinant subunit vaccine. It combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity as people age.

- The safety and efficacy of Shingrix were based on placebo-controlled trials in patients ≥ 50 years old and ≥ 70 years old.

  — Compared to placebo, Shingrix reduced the risk of developing herpes zoster by 97.2% (95% CI: 93.7, 99.0) in patients ≥ 50 years old, and by 89.8% (95% CI: 84.3, 93.7) in patients ≥ 70 years old.
  — Moreover, by preventing shingles, Shingrix significantly reduced the overall incidence of PHN, a common complication associated with shingles.

- Shingrix is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of Shingrix.

- Warnings and precautions for Shingrix include preventing and managing allergic vaccine reactions.

- In subjects ≥ 50 years old, solicited local adverse reactions with Shingrix use were pain, redness, and swelling. Solicited general adverse reactions were myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.

- Shingrix is administered intramuscularly in two doses (0.5 mL each) at month 0 followed by a second dose anytime between 2 to 6 months later. Refer to the Shingrix drug label for more details.

- GlaxoSmithKline plans to launch Shingrix shortly. Shingrix will be available as a single-dose vial for reconstitution with an accompanying vial of an adjuvant suspension component.